Effective and enduring surgical treatment for targeted therapy-related paronychia: A retrospective study.
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
21 Oct 2022
21 Oct 2022
Historique:
entrez:
25
10
2022
pubmed:
26
10
2022
medline:
27
10
2022
Statut:
ppublish
Résumé
The development of targeted therapy has improved treatment outcomes for patients with non-small cell lung cancer (NSCLC). However, paronychia, a common adverse effect of targeted therapy, remains burdensome. Although conservative treatments for paronychia have been well reported in the literature, studies on the efficacy of surgical partial matricectomy for paronychia, are scarce. This study aimed to evaluate the effect of surgical partial matricectomy in targeted therapy-induced paronychia in patients with NSCLC. This retrospective cohort study included 11 patients with a total of 18 lesions on the big toes. Data on lung cancer stages, types and duration of targeted therapy, onset of paronychia, pain scale scores, conservative treatments, course of matricectomy, paronychia-free interval after matricectomy, and wound condition were collected from medical records. The Wilcoxon signed-rank test was used for analysis. The mean pain scale score after matricectomy was significantly lower than that after conservative treatments (1.00 ± 0.00 vs 2.94 ± 0.87; P < .001) and before treatment (1.00 ± 0.00 vs 3.06 ± 0.80; P < .001). The mean duration of matricectomy was significantly shorter than that of conservative treatments (3.22 ± 1.00 vs 56.56 ± 52.29 weeks; P < .001). Surgical partial matricectomy is an effective and enduring intervention for targeted therapy-related paronychia. It provides a shorter course of treatment, reduced pain, and improved appearance of the healed wound. Furthermore, surgical partial matricectomy could result in a better quality of life during targeted therapy than that of conservative treatments.
Identifiants
pubmed: 36281135
doi: 10.1097/MD.0000000000031208
pii: 00005792-202210210-00058
pmc: PMC9592431
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e31208Informations de copyright
Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to disclose.
Références
de Groot PM, Wu CC, Carter BW, et al. The epidemiology of lung cancer. Transl Lung Cancer Res. 2018;7:220–33.
da Cunha SG, Shepherd FA, Tsao MS. EGFR mutations and lung cancer. Annu Rev Pathol. 2011;6:49–69.
Dearden S, Stevens J, Wu YL, et al. Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap). Ann Oncol. 2013;24:2371–6.
Leggit JC. Acute and chronic paronychia. Am Fam Physician. 2017;96:44–51.
Califano R, Tariq N, Compton S, et al. Expert consensus on the management of adverse events from EGFR tyrosine kinase inhibitors in the UK. Drugs. 2015;75:1335–48.
Garden BC, Wu S, Lacouture ME. The risk of nail changes with epidermal growth factor receptor inhibitors: a systematic review of the literature and meta-analysis. J Am Acad Dermatol. 2012;67:400–8.
Goto H, Yoshikawa S, Mori K, et al. Effective treatments for paronychia caused by oncology pharmacotherapy. J Dermatol. 2016;43:670–3.
Relhan V, Goel K, Bansal S, et al. Management of chronic paronychia. Indian J Dermatol. 2014;59:15–20.
Hanania HL, Pacha O, Heberton M, et al. Surgical intervention for paronychia induced by targeted anticancer therapies. Dermatol Surg. 2021;47:775–9.
Zuber TJ. Ingrown toenail removal. Am Fam Physician. 2002;65:2547–52, 2554.
Sollena P, Mannino M, Tassone F, et al. Efficacy of topical beta-blockers in the management of EGFR-inhibitor induced paronychia and pyogenic granuloma-like lesions: case series and review of the literature. Drugs Context. 2019;8:212613–212613.
Sibaud V, Casassa E, D’Andrea M. Are topical beta-blockers really effective “In real life” for targeted therapy-induced paronychia. Support Care Cancer. 2019;27:2341–3.
Capriotti KD, Anadkat M, Choi J, et al. A randomized phase 2 trial of the efficacy and safety of a novel topical povidone-iodine formulation for cancer therapy-associated paronychia. Invest New Drugs. 2019;37:1247–56.
Melosky B, Leighl NB, Rothenstein J, et al. Management of EGFR TKI-induced dermatologic adverse events. Curr Oncol. 2015;22:123–32.
Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer. 2006;6:803–12.
Chen K-L, Lin C-C, Cho Y-T, et al. Comparison of skin toxic effects associated with gefitinib, erlotinib, or afatinib treatment for non–small cell lung cancer. JAMA Dermatol. 2016;152:340–2.
Chu CY, Choi J, Eaby-Sandy B, et al. Osimertinib: a novel dermatologic adverse event profile in patients with lung cancer. Oncologist. 2018;23:891–9.
Masago K, Irie K, Fujita S, et al. Relationship between paronychia and drug concentrations of epidermal growth factor receptor tyrosine kinase inhibitors. Oncology. 2018;95:251–6.
Rockwell PG. Acute and chronic paronychia. Am Fam Physician. 2001;63:1113–6.
Olamiju B, Bhullar S, Coleman EL, et al. Management of paronychia with pseudopyogenic granulomas secondary to epidermal growth factor receptor inhibitors: an assessment of topical timolol and the need for multiple medical and procedural therapies. J Am Acad Dermatol. 2021;84:806–8.
Alessandrini A, Sechi A, Merli Y, et al. Intralesional steroid treatment for the intermediate stage of retronychia: a pilot study. Dermatol Ther. 2020;33:e14174.